The power and potential of Xolacta.
The Tiny Cargo Company is pioneering the development of drugs for application in the treatment of ionizing radiation exposure.
Applications with meaningful patient benefits.
Our unique technology isolates exosomes from cow’s milk at an industrial scale, then the exosomes are loaded with our peptide (alpha-CT11) to create a novel new drug - Xolacta..
The Tiny Cargo Company is investigating the use of Xolacta in the treatment of exposure to a lethal dose of ionizing radiation and as a radio protectant for healthy cells during radiation treatment.
Exploring the the use of Xolacta in the treatment of high level radiation exposure.
We live in a nuclear world and currently there are zero treatments for lethal radiation exposure. We aim to change that. Xolacta has been reviewed by the Biomedical Advanced Research and Development Agency (BARDA) as a medical countermeasure and greenlighted for further trials. This is a breakthrough and we will keep you updated as trials continue.
Investigating the protection of healthy cells from the side effects of radiation exposures during cancer treatment.
The side effects of radiation treatment during cancer treatment can be devastating. Xolacta is being developed as the first whole of body radioprotectant therapy with potentially lifechanging impacts for cancer patients around the world.
Xolacta contains revolutionary, proprietary drugs, using milk exosomes as a novel drug delivery platform – able to signal, target and offload vital therapies to the exact site where they’re needed most.
FDA Safety Trials Process.
We are under way with the process to secure regulatory approval.
Projected Development Time Line.
"Milk exosomes contain the potential to stand as a new modality of drug delivery- with an all natural packaging system, Tiny Cargo is poised to revolutionize peptide therapeutics"
Spencer Marsh
Chief Scientific Officer
